Tag: Diabetes: Misc.
Semaglutide Ups Risk for Nonarteritic Anterior Ischemic Optic Neuropathy in Diabetes
Semaglutide use associated with increased risk for NAION at the two-, three-, and four-year time point from the index date
ACC: Microplastic Exposure Tied to Chronic Disease Prevalence
Significant associations seen for high blood pressure, diabetes, and stroke
Low-Glucose Alerts Beneficial for Insulin-Treated Drivers With Diabetes
Low-glucose alerts improve time below range for drivers with T1D and reduce incidence of low glucose for all insulin-treated drivers
GLP-1 RA Use Tied to Better Kidney Transplant Outcomes in Patients With Diabetes
Findings show benefits for patient survival
1990 to 2021 Saw Increase in Global Burden of Diabetic Nephropathy
Burden is projected to continue increasing through 2050, and is related to sociodemographic index
No Weight Loss Benefit Seen for Neoadjuvant Semaglutide Before Weight Loss Surgery
No benefits seen in terms of weight loss, diabetes remission, surgery safety
Recent Decade Saw No Change in Diabetes Prevalence in U.S. Adults
However, glycemic control worsened, with the trend most pronounced among younger adults aged 20 to 44 years
Continuous Glucose Monitors Overestimate Glycemic Responses
Variation in CGM bias by postprandial test, with glycemic index for commercial fruit smoothie higher with CGM versus capillary sampling
One-Hour Glucose on OGTT at Three Months Postpartum Predicts Dysglycemia
One-hour glucose was strongest predictor of dysglycemia on regression analyses, followed by two-hour glucose
FDA Approves First Rapid-Acting Insulin Biosimilar for Patients With Diabetes
Merilog administered subcutaneously five to 10 minutes before mealtime helps improve glycemic control
